CLRB Stock — Cellectar Biosciences Inc.: Cash, EV, Pipeline

Share price

$2.38

Market cap

$22.5M

Cash

$34.0M

Enterprise value

-$11.5M

Balance sheet

Cash	$34.0M
Debt	$0.0M
Net cash	$34.0M
Enterprise value	-$11.5M
Basic shares	8.3M shares
Fully diluted shares	53.2M shares
Fully diluted market cap	$126.6M
Cash per share	$4.10

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CLRB daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 6 - Nov 17	CLR 131	Phase 1	Pediatric Solid Tumor; Pediatric Lymphoma; Pediatric Brain Tumor	—
Mar 14 - Apr 25	Iopofosine I 131	Phase 1	Breast Cancer	—
Feb 12 - Mar 25	Iopofosine I 131	Phase 3	Waldenstrom Macroglobulinaemia; Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinaemia Refractory	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Iopofosine I 131

Phase 2 · Active Modality: radiopharmaceutical (phospholipid radioconjugate)

Aliases iopofosine, CLR 131

Target phospholipid (phospholipid radioconjugate)

Indications

Relapsed/refractory Waldenstrom macroglobulinemia (WM) (Phase 2)
Relapsed/refractory multiple myeloma (MM) (Phase 2)
Relapsed/refractory CNS lymphoma (CNSL) (Phase 2)
Pediatric high-grade glioma (HGG) (Phase 1)
Recurrent head & neck cancer (+ external beam radiation) (Phase 1)

Catalysts

— 2026 (initiation underway)

Status note Beta-emitting iodine-131 PRC. CLOVER WaM Phase 2 (pivotal registration, r/r WM ≥2 prior lines incl. BTKi failure): primary endpoint met, MRR 61.8%, ORR 83.6%, mDOR 17.8 months; 12-month follow-up reported May 5, 2026. Breakthrough Therapy Designation (r/r WM, Jun 4, 2025); EMA SAWP advised a Conditional Marketing Authorization filing for post-BTKi refractory WM could be acceptable (Oct 6, 2025). Phase 3 confirmatory study activities initiated Jun 2026. CLOVER-1 Phase 2b (r/r MM, r/r CNSL) closed to enrollment, patients in follow-up. Fatalities have occurred in patients post-treatment with iopofosine. $35M upfront + up to $105M milestone-based financing (May 5, 2026) funds Phase 3 initiation.

CLR 121125

Phase 1 · Active Modality: radiopharmaceutical (phospholipid radioconjugate)

Aliases CLR 125

Target phospholipid (phospholipid radioconjugate)

Indications

Triple-negative breast cancer (TNBC) (Phase 1)

Status note Iodine-125 Auger-emitting program; Phase 1b dose-finding study in TNBC.

CLR 121225

Stage not disclosed · Active Modality: radiopharmaceutical (phospholipid radioconjugate)

Aliases CLR 225

Target phospholipid (phospholipid radioconjugate)

Status note Actinium-225 based PRC listed as a lead program; no trial detail in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Iopofosine I 131
Lead indication	Waldenstrom Macroglobulinaemia
Lead phase	Phase 3
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07766421	Phase 3	Not yet recruiting	Sponsor	CLRB	—	Waldenstrom Macroglobulinaemia; Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinaemia Refractory	—
NCT02952508	Phase 2	Active, not recruiting	Sponsor	CLRB	—	Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia	—
NCT07311993	Phase 1	Recruiting	Sponsor	CLRB	—	Breast Cancer	—
NCT05610891	Phase 1	Active, not recruiting	Sponsor	CLRB	—	High-Grade Glioma	—
NCT03478462	Phase 1	Active, not recruiting	Sponsor	CLRB	—	Pediatric Solid Tumor; Pediatric Lymphoma; Pediatric Brain Tumor	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Cellectar Biosciences, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

CLRB — Cellectar Biosciences Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials